CO7160119A2 - Derivados de imidazo[1,2-b]piridazina como inhibidor de cinasa - Google Patents
Derivados de imidazo[1,2-b]piridazina como inhibidor de cinasaInfo
- Publication number
- CO7160119A2 CO7160119A2 CO14286593A CO14286593A CO7160119A2 CO 7160119 A2 CO7160119 A2 CO 7160119A2 CO 14286593 A CO14286593 A CO 14286593A CO 14286593 A CO14286593 A CO 14286593A CO 7160119 A2 CO7160119 A2 CO 7160119A2
- Authority
- CO
- Colombia
- Prior art keywords
- imidazo
- kinase inhibitor
- compound
- pyridazine derivatives
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención está destinada a proporcionarun compuesto o una sal farmacológicamente aceptable del mismoel cual es útil en el tratamiento de un tumor a través delefecto inhibidor de la actividad de la enzima ROS1 cinasa yel efecto inhibidor de la enzima NTRK cinasa. La presenteinvención proporciona un compuesto que tiene estructuraimidazo[1,2-b]piridazina representado por la fórmula general(I) o una sal farmacológicamente aceptable del mismo, y unacomposición farmacéutica que comprende al compuesto. En lafórmula, R1, G, T, Y1, Y2, Y3 e Y4 son como se definen en lapresente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012127079 | 2012-06-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7160119A2 true CO7160119A2 (es) | 2015-01-15 |
Family
ID=49711970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO14286593A CO7160119A2 (es) | 2012-06-04 | 2014-12-30 | Derivados de imidazo[1,2-b]piridazina como inhibidor de cinasa |
Country Status (32)
Country | Link |
---|---|
US (2) | US9187489B2 (es) |
EP (1) | EP2857404B1 (es) |
JP (1) | JP5814467B2 (es) |
KR (1) | KR101781255B1 (es) |
CN (1) | CN104520300B (es) |
AU (1) | AU2013272701B2 (es) |
BR (1) | BR112014029851B1 (es) |
CA (1) | CA2874819C (es) |
CO (1) | CO7160119A2 (es) |
CY (1) | CY1119607T1 (es) |
DK (1) | DK2857404T3 (es) |
ES (1) | ES2648228T3 (es) |
HK (1) | HK1207374A1 (es) |
HR (1) | HRP20171724T1 (es) |
HU (1) | HUE037221T2 (es) |
IL (1) | IL236075A (es) |
IN (1) | IN2014MN02497A (es) |
LT (1) | LT2857404T (es) |
MX (1) | MX357021B (es) |
MY (1) | MY170326A (es) |
NO (1) | NO2857404T3 (es) |
NZ (1) | NZ702574A (es) |
PH (1) | PH12014502721A1 (es) |
PL (1) | PL2857404T3 (es) |
PT (1) | PT2857404T (es) |
RS (1) | RS56625B1 (es) |
RU (1) | RU2635917C2 (es) |
SG (1) | SG11201408052WA (es) |
SI (1) | SI2857404T1 (es) |
TW (1) | TWI585088B (es) |
WO (1) | WO2013183578A1 (es) |
ZA (1) | ZA201408843B (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5503655B2 (ja) | 2008-09-22 | 2014-05-28 | アレイ バイオファーマ、インコーポレイテッド | Trkキナーゼ阻害剤としての置換イミダゾ[1,2b]ピリダジン化合物 |
JP5600111B2 (ja) | 2008-10-22 | 2014-10-01 | アレイ バイオファーマ、インコーポレイテッド | TRKキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピリミジン化合物 |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
KR101852169B1 (ko) | 2010-05-20 | 2018-04-26 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
CA2872645A1 (en) | 2012-05-30 | 2013-12-05 | Nippon Shinyaku Co., Ltd. | Aromatic heterocyclic derivative and pharmaceutical |
ES2715676T3 (es) | 2014-03-27 | 2019-06-05 | Janssen Pharmaceutica Nv | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1,4]diazepina como inhibidores de ros1 |
BR112016021507B1 (pt) * | 2014-03-27 | 2022-10-18 | Janssen Pharmaceutica Nv | Derivados de 4,5,6,7-tetra-hidro-pirazolo[1,5-a]pirimidina substituídos e derivados de 2,3-dihidro-1himidazo[1,2-b]pirazol como inibidores do ros1 e composição farmacêutica que os compreende |
MX2016013600A (es) * | 2014-04-25 | 2017-04-27 | Exelixis Inc | Método para tratar adenocarcinoma de pulmón. |
JP6914834B2 (ja) | 2014-11-16 | 2021-08-04 | アレイ バイオファーマ インコーポレイテッド | (S)−N−(5−((R)−2−(2,5−ジフルオロフェニル)−ピロリジン−1−イル)−ピラゾロ[1,5−a]ピリミジン−3−イル)−3−ヒドロキシピロリジン−1−カルボキサミド硫酸水素塩の結晶形 |
US20180140604A1 (en) | 2015-06-01 | 2018-05-24 | Loxo Oncology, Inc. | Methods of diagnosing and treating cancer |
US9902696B2 (en) | 2015-06-18 | 2018-02-27 | Cephalon, Inc. | 1,4-substituted piperidine derivatives |
US10919875B2 (en) | 2015-06-18 | 2021-02-16 | 89Bio Ltd | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
SI3322706T1 (sl) | 2015-07-16 | 2021-04-30 | Array Biopharma, Inc. | Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze |
AU2016344058A1 (en) | 2015-10-26 | 2018-05-17 | Array Biopharma Inc. | Point mutations in Trk inhibitor-resistant cancer and methods relating to the same |
CN106854174A (zh) * | 2015-12-08 | 2017-06-16 | 湖南华腾制药有限公司 | 一种4位取代哌啶衍生物的制备方法 |
BR112018070017A2 (pt) | 2016-04-04 | 2019-02-05 | Loxo Oncology Inc | métodos de tratamento de cânceres pediátricos |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
PL3800189T3 (pl) | 2016-05-18 | 2023-10-23 | Loxo Oncology, Inc. | Wytwarzanie (s)-n-(5-((r)-2-(2,5-difluorofenylo)pirolidyn-1-ylo)pirazolo[1,5-a]pirymidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu |
CN107400082A (zh) * | 2016-05-19 | 2017-11-28 | 湖南华腾制药有限公司 | 一种取代哌啶衍生物的制备方法 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
ES2948194T3 (es) | 2017-01-18 | 2023-09-01 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
US11028091B2 (en) | 2017-03-14 | 2021-06-08 | Daiichi Sankyo Company, Limited | Method for producing 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
CA3080157A1 (en) | 2017-10-26 | 2019-05-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
CN109748902B (zh) * | 2017-11-02 | 2020-11-06 | 杭州科巢生物科技有限公司 | 一种盐酸安罗替尼的制备方法 |
JP7041265B2 (ja) * | 2017-11-29 | 2022-03-23 | ソウル大学校産学協力団 | 抗-ros1抗体およびその用途 |
CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
MA52218A (fr) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc | Traitement de cancers associés à trk |
WO2020022323A1 (en) | 2018-07-24 | 2020-01-30 | Taiho Pharmaceutical Co., Ltd. | Heterobicyclic compounds for inhibiting the activity of shp2 |
CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
US20220081438A1 (en) | 2018-12-19 | 2022-03-17 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
JP7413346B2 (ja) * | 2019-03-06 | 2024-01-15 | 第一三共株式会社 | ピロロピラゾール誘導体 |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
KR20220007111A (ko) * | 2019-05-08 | 2022-01-18 | 티와이케이 메디슨즈, 인코포레이티드 | 키나아제 억제제로 사용되는 화합물 및 이의 응용 |
CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
AR122159A1 (es) * | 2020-05-28 | 2022-08-17 | Novartis Ag | Inhibidores de mll1 y agentes antineoplásicos |
CN114957259A (zh) * | 2021-02-25 | 2022-08-30 | 南京明德新药研发有限公司 | 氰基取代的芳香双环类化合物及其应用 |
EP4363420A1 (en) * | 2021-07-01 | 2024-05-08 | Anheart Therapeutics (Hangzhou) Co., Ltd. | Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof |
WO2023220967A1 (en) * | 2022-05-18 | 2023-11-23 | Anheart Therapeutics (Hangzhou) Co., Ltd. | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds |
CN114989176B (zh) * | 2022-07-08 | 2024-08-27 | 深圳市新樾生物科技有限公司 | 咪唑并哒嗪类衍生物及其应用 |
CN115197115A (zh) * | 2022-08-25 | 2022-10-18 | 成都金博汇康医药科技有限公司 | 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399780B1 (en) | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
EP1339680A1 (en) | 2000-09-01 | 2003-09-03 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
AU8664701A (en) | 2000-09-01 | 2002-03-22 | Glaxo Group Ltd | Oxindole derivatives |
JP2003231687A (ja) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
US20090227648A1 (en) | 2004-04-21 | 2009-09-10 | Astrazeneca Ab | Pyrazole derivatives useful for the treatment of cancer |
EP1832588A4 (en) | 2004-12-28 | 2009-09-02 | Takeda Pharmaceutical | IMIDAZOLE CONDENSE DERIVATIVE AND APPLICATIONS THEREOF |
SI2383268T1 (sl) | 2005-02-04 | 2016-02-29 | Astrazeneca Ab | Derivati pirazolilaminopiridina uporabni kot kinazni inhibitorji |
BRPI0608160A2 (pt) | 2005-02-16 | 2010-11-09 | Astrazeneca Ab | anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado |
PT1853588E (pt) | 2005-02-16 | 2008-08-25 | Astrazeneca Ab | Compostos químicos |
WO2007013673A1 (en) | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
US7776878B2 (en) * | 2005-08-01 | 2010-08-17 | Hoffmann-La Roche Inc. | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents |
DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
DE102006029447A1 (de) * | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel |
AU2007315234A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
WO2008058126A2 (en) * | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
WO2008072682A1 (ja) * | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾ[1,2-b]ピリダジン誘導体 |
JP2009227599A (ja) * | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | イミダゾピリダジン誘導体 |
WO2009140128A2 (en) * | 2008-05-13 | 2009-11-19 | Irm Llc | Compounds and compositions as kinase inhibitors |
JP5503655B2 (ja) * | 2008-09-22 | 2014-05-28 | アレイ バイオファーマ、インコーポレイテッド | Trkキナーゼ阻害剤としての置換イミダゾ[1,2b]ピリダジン化合物 |
KR101147550B1 (ko) | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물 |
WO2012005299A1 (ja) | 2010-07-07 | 2012-01-12 | 日本新薬株式会社 | Rosチロシンキナーゼ阻害剤 |
WO2012125667A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
-
2013
- 2013-05-31 TW TW102119261A patent/TWI585088B/zh active
- 2013-06-03 PT PT138013206T patent/PT2857404T/pt unknown
- 2013-06-03 CA CA2874819A patent/CA2874819C/en active Active
- 2013-06-03 AU AU2013272701A patent/AU2013272701B2/en active Active
- 2013-06-03 RS RS20171198A patent/RS56625B1/sr unknown
- 2013-06-03 PL PL13801320T patent/PL2857404T3/pl unknown
- 2013-06-03 SI SI201330798T patent/SI2857404T1/sl unknown
- 2013-06-03 JP JP2014519977A patent/JP5814467B2/ja active Active
- 2013-06-03 NZ NZ702574A patent/NZ702574A/en unknown
- 2013-06-03 IN IN2497MUN2014 patent/IN2014MN02497A/en unknown
- 2013-06-03 MY MYPI2014003346A patent/MY170326A/en unknown
- 2013-06-03 WO PCT/JP2013/065328 patent/WO2013183578A1/ja active Application Filing
- 2013-06-03 MX MX2014014803A patent/MX357021B/es active IP Right Grant
- 2013-06-03 LT LTEP13801320.6T patent/LT2857404T/lt unknown
- 2013-06-03 KR KR1020147033351A patent/KR101781255B1/ko active IP Right Grant
- 2013-06-03 NO NO13801320A patent/NO2857404T3/no unknown
- 2013-06-03 EP EP13801320.6A patent/EP2857404B1/en active Active
- 2013-06-03 CN CN201380041498.XA patent/CN104520300B/zh active Active
- 2013-06-03 BR BR112014029851-3A patent/BR112014029851B1/pt active IP Right Grant
- 2013-06-03 US US14/378,318 patent/US9187489B2/en active Active
- 2013-06-03 ES ES13801320.6T patent/ES2648228T3/es active Active
- 2013-06-03 RU RU2014153627A patent/RU2635917C2/ru active
- 2013-06-03 HU HUE13801320A patent/HUE037221T2/hu unknown
- 2013-06-03 SG SG11201408052WA patent/SG11201408052WA/en unknown
- 2013-06-03 DK DK13801320.6T patent/DK2857404T3/en active
-
2014
- 2014-12-02 ZA ZA2014/08843A patent/ZA201408843B/en unknown
- 2014-12-04 IL IL236075A patent/IL236075A/en active IP Right Grant
- 2014-12-04 PH PH12014502721A patent/PH12014502721A1/en unknown
- 2014-12-30 CO CO14286593A patent/CO7160119A2/es unknown
-
2015
- 2015-08-19 HK HK15108047.9A patent/HK1207374A1/xx unknown
- 2015-10-29 US US14/926,973 patent/US9751887B2/en active Active
-
2017
- 2017-11-10 HR HRP20171724TT patent/HRP20171724T1/hr unknown
- 2017-11-15 CY CY20171101204T patent/CY1119607T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO7160119A2 (es) | Derivados de imidazo[1,2-b]piridazina como inhibidor de cinasa | |
ECSP14013230A (es) | Compuesto de ciclopropanoamina | |
PE20151423A1 (es) | Derivados tetrahidropiranilo inhibidores del hcv | |
CR20150474A (es) | Inhibidores de bromodominios tetracíclicos | |
CO7180199A2 (es) | Imidazotriazincarbonitrilos útiles como inhibidores de cinasa | |
CL2017003032A1 (es) | Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste | |
CR20110620A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus | |
PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
UY33694A (es) | ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?. | |
ECSP14017584A (es) | Compuestos inhibidores de raf | |
ECSP12011880A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
TN2012000578A1 (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
DOP2013000142A (es) | Derivados de biciclo[3,2,1]octilamida y sus usos. | |
DOP2010000310A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas | |
CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
DOP2013000243A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
ECSP13012824A (es) | Derivados de (1,2,4)triazolo[4,3-a)quinoxalina como inhibidores de fosfodiesterasas | |
PE20151718A1 (es) | Compuestos piridinilpirazoloquinolina | |
BR112015029348A2 (pt) | inibidores da bace | |
DOP2013000051A (es) | Compuestos heterociclico y sus usos | |
CR20120146A (es) | Derivados de espirolactama y usos de los mismos | |
NI201000176A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. | |
AR092772A1 (es) | Derivado de 7-azaindol | |
UY32447A (es) | Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia | |
UY32448A (es) | Derivados de 3-benzofuranil-indol-2-ona-3-acetamidopiperazinas sustituidos, su preparacion y su aplicacion en terapeutica |